Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
8
×
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
life sciences
national
8
×
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
indiana blog main
indiana top stories
clinical trials
eli lilly
fda
pfizer
alzheimer's disease
cancer
abbvie
biogen
boehringer ingelheim
bristol-myers squibb
celgene
eisai
merck
What
bio
8
×
roundup
week
8
×
drug
moves
biogen
alzheimer’s
ceo
companies
debut
ipo
life
news
science
acquisitions
adu
aducanumab
america
amyloid
angst
annual
approved
arena’s
assessed
attention
bagged
beats
bids
big
biggest
billions
biogen’s
biotech
black
bosley's
bosley’s
bounty
brammer
bridge
bucks
Language
unset
Current search:
national
×
week
×
" boston top stories "
×
bio
×
@xconomy.com
4 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
5 years ago
Bio Roundup: Head and Spine Previews, Biogen Moves, IPO Dreams & More
@xconomy.com
5 years ago
Bio Roundup: Amyloid Angst, NASH News, Brammer Bagged & More
@xconomy.com
5 years ago
Bio Roundup: Sage Postpartum Help, Biogen Bids Adu, Heart Beats & More
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Bio Roundup: Moderna’s IPO, Arena’s Comeback, E-Cig Survey & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More